Appl. No 10/811,200 Amdt. December 7, 2004 Reply to Office Action of November 11, 2004

AMENDMENTS TO THE CLAYMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS:

1. (currently amended): A compound of Formula I

$$R^2$$
 R^0
 R^3
 R^4
 R^6
 R^5
 R^7

or a pharmaceutically acceptable salt thereof, wherein

R¹ and R² are independently hydrogen or unsubstituted C₁-C₃ alkyl;

R³ is hydrogen, oxo, or thioxo;

 R^0 is hydrogen or unsubstituted C_1 - C_3 alkyl provided that when R^3 is oxo or thioxo R^0 is absent:

1

- R⁴, R⁵, R⁶, and R⁷ are independently hydrogen, halogen, carboxyl, substituted or unsubstituted C₁-C₃ alkoxy, or substituted or unsubstituted C₁-C₃ alkyl;
- Q is -NR⁸-(CH₂)₀₋₆-, -NR⁹-C(O)-(CH₂)₀₋₆-, wherein 1 to 3 nonadjacent methylene units are replaced with O, NR¹⁰, S or a combination thereof;
- T is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted C₁-C₁₂-alkyl;

W is absent, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

Z is -(CH₂)₀₋₆-cycloalkylene-(CH₂)₀₋₆- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR^{12} , S or a combination thereof,

Reply to Office Action of November 11, 2004

- -(CH₂)₀₋₆-heterocycloalkylene-(CH₂)₀₋₆- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR¹², S or a combination thereof,
- -(CH₂)₀₋₆-arylene-(CH₂)₀₋₆- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR¹², S or a combination thereof,
- -(CH₂)₀₋₆-heteroarylene-(CH₂)₀₋₆- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR¹², S or a combination thereof,
- -(CH₂)₀₋₆-C(O)-NR¹¹-(CH₂)₀₋₆- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR¹², S or a combination thereof,
- -(CH₂)₀₋₆- NR¹¹-C(O)-(CH₂)₀₋₆- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR¹², S or a combination thereof,

$$- \left(\begin{matrix} R^{15} \\ \hline C \\ R^{14} \end{matrix} \right)$$

R¹⁵

wherein 1 to 6 nonadjacent combination thereof, or

units are replaced with O, NR¹², S or a

Z, when W is absent, is hydroxyl, substituted or unsubstituted C₁-C₁₂ alkyl wherein 1 to 6 nonadjacent methylene units are replaced with O, NR¹⁶, S or a combination thereof, or -(CH₂)₀₋₆-C(O)-NR¹⁶-(CH₂)₀₋₅-CH₃ wherein 0 to 6 nonadjacent methylene units are replaced with O, NR¹⁶, S or a combination thereof;

 R^8 , R^9 and R^{10} are independently hydrogen or substituted or unsubstituted C_1 - C_3 alkyl; R^{11} and R^{12} are independently substituted or unsubstituted C_1 - C_3 alkyl; and

R¹⁴ and R¹⁵ are independently hydrogen, substituted or unsubstituted C₁-C₃ alkoxy, substituted or unsubstituted C₁-C₃ alkyl, unsubstituted C₁-C₁₂ alkyl wherein 1 to 6 nonadjacent methylene units are replaced with O, or R¹⁴ and R¹⁵ together with the carbon to which they are attached form a 3- to 6-membered cycloalkylene or heterocycloalkylene ring; and

R¹⁶ is substituted or unsubstituted C₁-C₃ alkyl or hydrogen.

Appl. No 10/811,200 Amdt. December 7, 2004 Reply to Office Action of November 11, 2004

- 2. (original): A compound of claim 1, wherein R¹ and R², are hydrogen and R³ is oxo.
- 3. (original): A compound of claim 1, wherein R^4 , R^5 , R^6 , and R^7 are independently hydrogen, halogen, carboxyl, C_1 - C_3 alkoxy, or C_1 - C_3 alkyl.
- 4. (original): A compound of claim 3, wherein R⁴, R⁵, R⁶, and R⁷ are independently hydrogen, chlorine, fluorine, carboxyl, methoxy or methyl.
- 5. (original): A compound of claim 1, wherein R⁴, R⁶, and R⁷ are hydrogen and R⁵ is chlorine, fluorine, carboxyl, methoxy or methyl.
- 6. (original): A compound of claim 1, wherein Q is -NR⁸-(CH₂)₀₋₆-, or -NR⁹-C(O)-(CH₂)₀₋₆- wherein R⁸ and R⁹ are independently unsubstituted C_1 - C_3 alkyl.
- 7. (original): A compound of claim 6, wherein Q is -NH-(CH₂)₀₋₆-, or -NH-C(O)-(CH₂)₀₋₆-.
- 8. (original): A compound of claim 7, wherein Q is -NH-CH₂-, -NH -CH₂-CH₂-, -NH-CH₂-CH₂-O-CH₂-, or -NH-CH₂-CH₂-O-.
- 9. (original): A compound of claim 1, wherein T is unsubstituted aryl.
- 10. (currently amended): A compound of claim 1, wherein T is unsubstituted phenyl, naphthyl, biphenyl, 1,2,3,4-tetrahydro-naphthyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydroquinoxalinyl, or 1,2,3,4-tetrahydroindolyl.
- 11. (currently amended): A compound of claim 10, wherein T is 2-naphthyl [[,]] or biphen-4-yl . 1.2.3.4 tetrahydroquinolin 6-yl, or 1,2,3,4 tetrahydroquinolin 7-yl.
- 12. (original): A compound of claim 1, wherein T is substituted aryl

Reply to Office Action of November 11, 2004

13. (currently amended): A compound of claim 12, wherein T is substituted phenyl, naphthyl, biphenyl, 1,2,3,4-tetrahydroquinolinyl, 2-oxo-1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroquinoxalinyl, 1,2,3,4-tetrahydroinoxalinyl, 1,2,3,4-tetrahydroinoxalinyl, 1,2,3,4-tetrahydroinoxalinyl, 2,3-dihydroinolyl, 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazinyl, or 3,4-dihydro-2H-benzo[1,4]oxazinyl.

14. (original): A compound of claim 12, wherein T is phenyl substituted from 1 to 5 times with C₁-C₆ alkyl, halo, C₁-C₆ alkyl wherein 1 to 3 nonadjacent carbons are replaced with O, NR¹⁶, S or a combination thereof, (C₁-C₆ alkyl)-C(O)-O-(C₁-C₆ alkyl)₀₋₁-, (C₁-C₆ alkyl)-O-C(O)-(C₁-C₆ alkyl)₀₋₁-, (C₁-C₆ alkyl)-C(O)-N(R¹⁶)-, (C₁-C₆ alkyl)-NR¹⁶-C(O)-(C₁-C₆ alkyl)₀₋₁-, trifluoromethyl, (C₁-C₆ alkyl)-C(O)-NR¹⁶-(C₁-C₆ alkyl)₀₋₁-, HO-C(O)-(C₁-C₆ alkyl)₀₋₁-, (C₁-C₆ alkyl)-NR¹⁶- alkyl)-C(O)-(C₁-C₆ alkyl)₀₋₁-, (C₁-C₆ alkyl)-S(O)₂-NR¹⁶-(C₁-C₆ alkyl)₀₋₁-, (C₁-C₆ alkyl)-NR¹⁶- S(O)₂-(C₁-C₆ alkyl)₀₋₁-, or HO-(C₁-C₆ alkyl), wherein each R¹⁶ is independently H or C₁-C₆ alkyl or a combination thereof.

15. (original): A compound of claim 14, wherein T is 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-methoxyphenyl,3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-fluoro-2-trifluoromethylphenyl, 2-(2-acetoxy-ethyl)-phenyl, 3-(2-acetoxy-ethyl)-phenyl, 4-(2-acetoxy-ethyl)-phenyl, N,N-dimethyl-benzamide-4-yl, or 4-acetylaminophenyl.

16. (original): A compound of claim 1, wherein T is biphenyl substituted from 1 to 9 times with C_1 - C_6 alkyl, halo, C_1 - C_6 alkyl wherein 1 to 3 nonadjacent carbons are replaced with O, NR^{16} , S or a combination thereof, $(C_1$ - C_6 alkyl)-C(O)- $C(C_1$ - C_6 alkyl)-C(O)- $C(C_1$ - C_6 alkyl)-C(O)

Appl. No 10/811,200 Amdt. December 7, 2004 Reply to Office Action of November 11, 2004 $S(O)_2$ - $(C_1$ - C_6 alkyl $)_{0-1}$ -, or HO- $(C_1$ - C_6 alkyl), wherein each R^{16} is independently H or C_1 - C_6 alkyl)or a combination thereof.

- 17. (currently amended): A compound of claim 1, wherein T is naphthyl [[,]] or 1,2,3,4tetrahydroquinolinyl, 2-oxo-1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydronaphthyl, 1,2,3,4tetrahydroisoguinolinyl, 1,2,3,4-tetrahydroquinoxalinyl, 3,4-dihydro-2H-benzo[1,4]oxazinyl, 3oxo-3,4-dihydro-2H-benzo[1,4]oxazinyl, 2,3-dihydroindolyl, or-1,2,3,4-tetrahydroindolyl substituted from 1 to 7 times with, C1-C6 alkyl, halo, hydroxy, oxo, C1-C6 alkyl wherein 1 to 3 nonadjacent carbons are replaced with O, NR¹⁶, S or a combination thereof, (C₁-C₆ alkyl)-C(O)- $O-(C_1-C_6 \text{ alkyl})_{0-1}-, (C_1-C_6 \text{ alkyl})-O-C(O)-(C_1-C_6 \text{ alkyl})_{0-1}-, (C_1-C_6 \text{ alkyl})-C(O)-N(R^{16})-, (C_1-C_6 \text{ alkyl})_{0-1}-, (C_1-C_6 \text{ alkyl})-C(O)-N(R^{16})-, (C_1-C_6 \text{ alkyl})_{0-1}-, (C_1-C_6 \text{ alkyl})-C(O)-N(R^{16})-, (C_1-C_6 \text{ alkyl})-, (C_1$ alkyl)- NR^{16} -C(O)-(C₁-C₆ alkyl)₀₋₁-, trifluoromethyl, (C₁-C₆ alkyl)-C(O)- NR^{16} -(C₁-C₆ alkyl)₀₋₁-, $HO-C(O)-(C_1-C_6 \text{ alkyl})_{0-1}-$, $(C_1-C_6 \text{ alkyl})-C(O)-(C_1-C_6 \text{ alkyl})_{0-1}-$, $(C_1-C_6 \text{ alkyl})-S(O)_2-NR^{16}-(C_1-C_6 \text{ alkyl})_{0-1} C_6$ alkyl) c_{-1} , $(C_1-C_6$ alkyl)-NR¹⁶-S(O)₂- $(C_1-C_6$ alkyl) c_{-1} , or HO- $(C_1-C_6$ alkyl), wherein each R¹⁶ is independently H or C₁-C₆ alkyl or a combination thereof.
- 18. (currently amended): A compound of claim 17, wherein T is 6-methoxy-2-naphthyl, 7methoxy-2-naphthyl, 6-methyl-2-naphthyl, 6-hydroxy-2-naphthyl, 7-methyl-2-naphthyl, 6trifluoromethyl-2-naphthyl, 7-trifluoromethyl-2-naphthyl, 6-fluoro-2-naphthyl, 7-fluoro-2naphthyl, 6-chloro-2-naphthyl, 7-chloro-2-naphthyl, 6-(2-acetoxy-ethyl)-2-naphthyl [[,]] or 7-(2acetoxy-ethyl)-2-naphthyl, 1-(3-hydroxypropyl)-3,4-dihydro-2H quinolin-7-yl, 1-acetyl 3.4dihydro-2H quinolin-6-yl, 1-(4-thiazolylmothyl) 3,4-dihydro-2H quinolin-7-yl, 1-acetamidyl-3,4-dihydro-2H-quinolin-7-yl, or-1-(2-acetoxy ethyl) 3,4 dihydro-2H-quinolin 7-yl.
- 19. (currently amended): A compound of claim 1, wherein T is unsubstituted naphthyl, unsubstituted 4-trifluoromethylphenyl, unsubstituted 1,2,3,4-tetrahydroquinolin-7-yl, 1-(2ethoxy 2-exectivel) 5 indelyl, 1-(2-acetylaminoethyl)-5-indelyl, 1-(3-methoxypropyl) 5 indelyl, 1 acetamidyl 5 indolyl, 1-(2-acetoxyethyl)-5-indolyl, 1-(3 methoxy-3-oxopropyl)-5-indolyl, 1-(2-methoxy 2 exectivel) 5 indelyl, 1 (2 ethoxy 2 exectivel) 6 indelyl, 1 (2-acetylaminoethyl) 6 indolyl, 1 (3 methoxypropyl) 6 indolyl, 1 acetamidyl-6-indolyl, 1 (2-acetoxyethyl)-6-indolyl, 1 (3-methoxy 3-exepropyl) 6-indelyl, 1-(2-methoxy-2-execthyl) 6-indelyl, 4-(2-ethoxy-2oxoethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 3-oxo-3,4-dihydro-2H-

Appl. No 10/811,200 Amdt. December 7, 2004 Reply to Office Action of November 11, 2004 benzo[1,4]oxazin-6-yl, 4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 4-(2acetylaminoethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 4-acetamidyl-3-oxo-3,4dihydro-2H-benzo[1,4]oxazin-6-yl, 4-(2-acetoxyethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 4-(3-methoxy-3-oxopropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl [[,]] or 4-(2methoxy-2-oxoethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 1-(3-hydroxypropyl)-3,4dihydro 2H-quinolin-7-yl, 1-(3-hydroxypropyl) 2-oxo-3,4-dihydro 2H quinolin-7-yl, 1-acetyl-3.4 dihydro 2H quinolin 6-yl, 1-acetyl-2-oxo-3,4-dihydro-2H quinolin-6-yl, 1 (4thiazolylmethyl) 3,4 dihydro-2H-quinolin-7-yl, 1-acetamidyl-3,4 dihydro-2H quinolin-7-yl, 1acetamidyl-2-oxo-3,4-dihydro-2H-quinolin-7-yl, 1-acetamidyl 3,4-dihydro-2H-quinolin-6-yl, 1acetamidyl-2-oxo-3,4-dihydro-2H-quinolin-6-yl, 1-(2 acetylaminoethyl)-3,4-dihydro-2Hquinolin-7-yl, 1-(3-methoxy-3-oxopropyl)-3,4-dihydro-2H quinolin-7-yl, 1 (3-methoxypropyl)-3,4 dihydro 2H quinolin 7 yl, 1 (2 methexy 2 execthyl) 3,4 dihydro 2H quinolin 7 yl, 1 (2ethoxy-2-execthyl)-3,4-dihydro 2H quinolin 7 yl, 1 (2 acetylamineethyl)-3,4-dihydro 2H quinolin 6-yl, 1-(3-methoxy 3-oxopropyl) 3,4-dihydro-2II-quinolin 6-yl, 1-(3-methoxypropyl) 3,4-dihydro 2H quinolin 6-yl, 1-(2-methoxy-2-oxoethyl)-3,4-dihydro 2H-quinolin-6-yl, 1-(2ethoxy 2 exective) 3,4 dihydro-2H-quinolin 6 yl, 2 exe-1,2,3,4 tetrahydro-2H quinolin 7 yl, 2exe-1.2.3.4-tetrahydre-2H-quinolin-6-yl, 1 (2 acetylarnineethyl)-2 exe-3,4-dihydre-2Hquinolin 7 vl. 1 (3 methoxy 3 exepropyl) 2 exe 3,4 dihydro-2H quinolin 7-yl, 1 (3methoxypropyl) 2 oxo 3,4 dihydro 2H-quinolin 7 yl, 1 (2 methoxy 2 oxoethyl) 2 oxo 3,4 dihydro 2H quinelin 7 yl, I (2 ethoxy 2 excethyl) 2 exo-3,4 dihydro 2H quinelin 7-yl, 1-(2ncetylaminoethyl) 2 oxo 3,4-dihydro-2H-quinolin-6 yl, 1 (3 methoxy-3-oxopropyl) 2 oxo 3,4dihydro-2H quinolin 6-yl, 1-(3-methoxypropyl)-2-oxo-3,4-dihydro-2H quinolin-6-yl, 1-(2methoxy-2 oxoethyl) 2 oxo-3,4 dihydro 2H-quinolin-6-yl, 1 (2 ethoxy-2 oxoethyl) 2 oxo-3,4dihydro 2H-quinolin-6-yl, 1-(2-acetoxyethyl)-2 oxo-3,4-dihydro 2H-quinolin-6-yl, 1-(2acetoxyethyl) 2-oxo-3,4-dihydro-2H-quinolin-7-yl, 1-(2-acetoxyethyl) 3,4-dihydro-2H-quinolin-6 yl or I (2-acetoxyethyl) 3,4 dihydro 2H quinolin 7 yl.

20-26. (canceled)

27. (currently amended): A compound of claim 1, wherein T is N substituted 1,2,3,4-tetrahydroquinolin-7-yl, N substituted 1,2,3,4 tetrahydroquinolin-6-yl, N substituted 2-oxo-

Reply to Office Action of November 11, 2004

1,2,3,4 tetrahydroquinolin-7-yl, N-substituted 2-oxo-1,2,3,4 tetrahydroquinolin-6-yl, N-substituted 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, N-substituted 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl, N-substituted 2-oxo-4a,8a-dihydro-2H-chromen-7-yl, N-substituted 2,3-dihydroindol-6-yl, N-substituted 2,3-dihydroindol-6-yl, N-substituted 2,3-dihydroindol-5-yl [[,]] or N-substituted 2-oxo-2,3-dihydroindol-5-yl, N-substituted 6-indolyl or N-substituted 5-indolyl.

28. (original): A compound of claim 27, wherein the N-substituent is C_1 - C_6 alkyl, C_1 - C_6 alkyl wherein 1 to 3 nonadjacent carbons are replaced with O, NR ¹⁶, S or a combination thereof, (C_1 - C_6 alkyl)-C(O)- C_1 - C_2 - C_1 - C_2 - C_1 - C_2 - C_1 - C_2 - C_2 - C_1 - C_2 - $C_$

29. (original): A compound of claim 1, wherein Z is

wherein 1 to 6 nonadjacent

units are replaced with O.

30. (original): A compound of claim 1, wherein R14 and R15 are hydrogen.

31. (original): A compound of claim 1, wherein Z is

-(CH₂)₀₋₆-C(O)-NR¹¹-(CH₂)₀₋₆- wherein 0 to 6 nonadjacent methylene units are replaced with O, NR¹². S or a combination thereof; or

- $(CH_2)_{0.6}$ - NR^{11} -(C(O)- $CH_2)_{0.6}$ - wherein 0 to 6 nonadjacent methylene units are replaced with O, NR^{12} , S or a combination thereof; and

Appl. No 10/811,200
Amdt. December 7, 2004
Reply to Office Action of November 11, 2004
R¹¹ and R¹² are as defined in claim 1.

- 32. (original): A compound of claim 29, wherein Z is -O-(CH₂)₂₋₃-O-(CH₂)₁₋₂-, -O-(CH₂)₃₋₄-O-, O-(CH₂)₁₋₂-, $-(CH_2)$ ₂₋₃-O-(CH₂)₂₋₃-O-(CH₂)₀₋₁-, -C(O)-NR¹¹-(CH₂)₂-, -C(O)-NR¹¹-(CH₂)₂-O-, or -O-(CH₂)₃-S-(CH₂)₁-; and R¹¹ is as defined in claim 1.
- 33. (canceled)
- 34. (original): A compound of claim 1, wherein Z is -O-(CH₂)₃-O-(CH₂)-.
- 35. (original): A compound of claim 1, wherein W is unsubstituted or substituted phenyl.
- 36. (original): A compound of claim 1, wherein W is 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-fluoro-2-trifluoromethylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2-chloro-4-fluorophenyl, 4-fluoro-2-trifluoromethylphenyl, 2-(2-acetoxy-ethyl)-phenyl, 3-(2-acetoxy-ethyl)-phenyl, 4-(2-acetoxy-ethyl)-phenyl, N,N-dimethyl-benzamide-4-yl, or 4-acetylaminophenyl.
- 37. (original): A compound of claim 1, wherein W is 2-methoxyphenyl.
- 38-40. (canceled)
- 41. (original): A compound of claim 1, wherein Z is $-O-(CH_2)_3-O-CH_2-$, and W is 2-methoxyphenyl.
- 42. (currently amended): A compound of claim 1, wherein Q is -NH-CH₂- or -NR⁸-CH₂-; T is unsubstituted naphthyl, unsubstituted 4-trifluoromethylphenyl, unsubstituted 1,2,3,4-

Appl. No 10/811,200 Amdr. December 7, 2004 Reply to Office Action of November 11, 2004 tetrahydroquinolin 7-yl, 1-(2 ethoxy 2-oxoethyl) 5-indolyl, 1-(2-acetylaminoethyl) 5-indolyl, 1-(3-methexypropyl) 5 indolyl, 1-acctamidyl 5 indolyl, 1 (2-acctoxyethyl)-5 indolyl, 1-(3methoxy-3 exepropyl) 5 indolyl, 1-(2 methoxy-2 execthyl) 5 indolyl, 1 (2 ethoxy-2 execthyl)-6-indolyl, 1-(2-acetylaminoethyl) 6-indolyl, 1-(3-methoxypropyl) 6-indolyl, 1-acetamidyl-6indolyl, 1 (2-acctoxyethyl) 6-indolyl, 1 (3-methoxy-3-oxopropyl) 6-indolyl, 1-(2-methoxy-2oxoethyl)-6 indolyl, 4-(2-ethoxy-2-oxoethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 3oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2Hbenzo[1,4]oxazin-6-yl, 4-(2-acetylaminoethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 4acetamidyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 4-(2-acetoxyethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 4-(3-methoxy-3-oxopropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl [[,]] or 4-(2-methoxy-2-oxoethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 1-(3hydroxypropyl) 3,4-dihydro 2H quinolin 7 yl, 1-(3-hydroxypropyl) 2 oxo-3,4-dihydro 2H quinolin 7-yl, 1-acetyl-3,4-dihydro-2H-quinolin-6-yl, 1-acetyl-2-oxo-3,4-dihydro-2H-quinolin-6yl, 1 (4 thiazolylmethyl) 3,4-dihydro-2H-quinolin 7-yl, 1-acetamidyl 3,4-dihydro-2H-quinolin-7-yl, 1-acetamidyl-2-oxo-3,4 dihydro-2H quinolin-7-yl, 1-acetamidyl-3,4 dihydro-2H-quinolin-6-yl, 1-acetamidyl-2-exe-3,4 dihydre-2H-quinelin 6-yl, 1-(2-acetylamineethyl) 3,4-dihydre-2H quinolin 7-yl, 1-(3-methoxy-3-oxopropyl)-3,4-dihydro-2H-quinolin 7-yl, 1-(3-methoxypropyl)-3,4-dihydro-2H-quinolin 7-yl, 1 (2-methoxy 2-oxoethyl) 3,4-dihydro-2H quinolin 7-yl, 1-(2othoxy 2 execthyl) 3,4-dihydro 2H quinolin 7-yl, 1-(2-acetylaminoethyl) 3,4-dihydro 2H quinolin-6 yl, 1 (3-methoxy 3-oxopropyl) 3,4-dihydro 2H quinolin-6 yl, 1 (3-methoxypropyl)-3,4 dihydro 2H quinolin-6 yl, 1-(2 methoxy 2 oxoethyl)-3,4 dihydro 2H quinolin 6 yl, 1 (2ethoxy 2 excethyl) 3,4-dihydro 2H-quinolin 6-yl, 2 exc-1,2,3,4-tetrahydro 2H-quinolin 7 yl, 2 oxo 1,2,3,4 tetrahydro 2H quinolin 6 yl, 1 (2 acetylaminoethyl) 2 oxo 3,4 dihydro 2H quinolin 7 yl, 1 (3-methoxy 3-oxopropyl) 2-oxo 3,4 dihydro 2H quinolin 7-yl, 1 (3methoxypropyl) 2 exo-3,4 dihydro-2H quinolin-7 yl, 1 (2-methoxy-2-exo-thyl) 2 exo-3,4dihydro 2H quinolin 7 yl, 1 (2 ethoxy-2 oxoethyl) 2 oxo 3,4-dihydro 2H quinolin 7 yl, 1-(2 acetylaminoethyl)- 2 oxo 3,4-dihydro 2H-quinolin-6-yl, 1 (3 methoxy 3 oxopropyl)- 2 oxo-3,4dihydro-2H quinolin-6-yl, 1-(3-methoxypropyl)-2-oxo-3,4-dihydro-2H quinolin-6-yl, 1-(2methoxy 2-exoethyl) 2-exo-3,4 dihydro-2H quinolin 6 yl, 1-(2 ethexy-2 exeethyl) 2-exo-3,4dihydro 2H quinolin 6 yl, 1 (2-acetoxyethyl) 2 oxo 3,4 dihydro 2H quinolin 6 yl, 1 (2Appl. No 10/811,200
Amdt. December 7, 2004
Reply to Office Action of November 11, 2004
acetoxyethyl) 2 exo-3,4 dihydro-2H-quinolin-7 yl, 1 (2 acetoxyethyl) 3,4-dihydro-2H-quinolin-6 yl or 1-(2-acetoxyethyl)-3,4-dihydro-2H-quinolin-7 yl; and R⁸ is C₁-C₃ alkyl.

43. (original): A compound of claim 1 having the formula II or III

$$R^2$$
 R^3
 R^4
 R^6
 R^5
 R^7
 R^7
 R^8
 R^8
 R^8
 R^8
 R^8
 R^8
 R^8
 R^8
 R^9
 R^9

or a pharmaceutically acceptable salt thereof, wherein

 R^{1} , R^{2} , R^{3} , R^{4} , R^{5} , R^{6} , R^{7} , R^{8} , R^{9} , R^{10} , R^{11} , R^{12} , R^{14} , R^{15} , R^{16} , Q, T, Z, and W are as defined above in claim 1.

44. (currently amended): A compound of Formula IV or V

Reply to Office Action of November 11, 2004

H
N
Reply to Office Action of November 11, 2004

H
N
R
17
R
17
R
17
R
17
R
17

or a pharmaceutically acceptable salt thereof, wherein

T is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; W is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and R^{17} is hydrogen or C_1 - C_3 alkyl.

45. (original): A compound of claim 44, wherein T is substituted aryl.

46. (currently amended): A compound of claim 45, wherein T is substituted phenyl, naphthyl, biphenyl, 1,2,3,4 tetrahydroquinolinyl, 2 oxo 1,2,3,4 tetrahydroquinolinyl, 1,2,3,4 tetrahydroquinoxalinyl, 1,2,3,4 tetrahydroinoxalinyl, 1,2,3,4 tetrahydroinoxalinyl, 1,2,3,4 tetrahydroindolyl, 2,3-dihydroindolyl, 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazinyl, or 3,4 dihydro-2H-benzo[1,4]oxazinyl.

47. (currently amended): A compound of claim 44, wherein T is naphthyl [[,]] or 1,2,3,4-tetrahydroquinolinyl, 2 exe-1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydronaphthyl, 1,2,3,4-tetrahydroisoquinolinyl, 1,2,3,4-tetrahydroquinoxalinyl, 3,4-dihydro-2H-benzo[1,4]exazinyl, 3-exe-3,4-dihydro-2H-benzo[1,4]exazinyl, 2,3-dihydroindelyl, or 1,2,3,4-tetrahydroindelyl substituted from 1 to 7 times with, C₁-C₆ alkyl, halo, hydroxy, exe, C₁-C₆ alkyl wherein 1 to 3 nonadjacent carbons are replaced with O, NR¹⁶, S or a combination thereof, (C₁-C₆ alkyl)-C(O)-O-(C₁-C₆ alkyl)₀₋₁-, (C₁-C₆ alkyl)-O-C(O)-(C₁-C₆ alkyl)₀₋₁-, (C₁-C₆ alkyl)-C(O)-N(R¹⁶)-, (C₁-C₆

Appl. No 10/811,200
Amdt. December 7, 2004
Reply to Office Action of November 11, 2004
alkyl)- NR¹⁶-C(O)-(C₁-C₆ alkyl)₀₋₁-, trifluoromethyl, (C₁-C₆ alkyl)-C(O)-NR¹⁶-(C₁-C₆ alkyl)₀₋₁-,
HO-C(O)-(C₁-C₆ alkyl)₀₋₁-, (C₁-C₆ alkyl)-C(O)-(C₁-C₆ alkyl)₀₋₁-, (C₁-C₆ alkyl)-S(O)₂-NR¹⁶-(C₁-C₆ alkyl)₀₋₁-, (C₁-C₆ alkyl)-NR¹⁶-S(O)₂-(C₁-C₆ alkyl)₀₋₁-, or HO-(C₁-C₆ alkyl), wherein each R¹⁶ is independently H or C₁-C₆ alkyl or a combination thereof.

48. (currently amended): A compound of claim 44, wherein T is unsubstituted naphthyl, unsubstituted 4-trifluoromethylphenyl, unsubstituted 1,2,3,4-tetrahydroquinolin-7-yl, 1-(2ethoxy 2 execthyl)-5-indelyl, 1 (2-acetylaminoethyl) 5 indelyl, 1-(3 methoxypropyl) 5-indelyl, 1-acetamidyl 5 indolyl,-1-(2-acetoxyethyl)-5 indolyl, 1-(3 methexy-3-oxopropyl)-5 indolyl, 1-(2 methoxy 2 excethyl) 5-indolyl, 1 (2 ethoxy 2 excethyl) 6-indolyl, 1 (2 acetylaminoethyl) 6indolyl, 1-(3-methoxypropyl) 6-indolyl, 1 acetamidyl-6-indolyl, 1-(2-acetoxyethyl)-6-indolyl, 1-(3-methoxy 3-exepropyl)-6-indelyl, 1-(2-methoxy-2-execthyl)-6-indelyl, 4-(2-ethoxy-2oxoethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 3-oxo-3,4-dihydro-2Hbenzo[1,4]oxazin-6-yl, 4-(3-methoxypropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 4-(2acetylaminoethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 4-acetamidyl-3-oxo-3,4dihydro-2H-benzo[1,4]oxazin-6-yl, 4-(2-acetoxyethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 4-(3-methoxy-3-oxopropyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl [[,]] or 4-(2methoxy-2-oxoethyl)-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, 1-(3 hydroxypropyl) 3,4dihydro-2H quinolin 7-yl, 1-(3-hydroxypropyl) 2-oxo-3,4 dihydro-2H-quinolin-7-yl, 1-acetyl-3,4-dihydro 2H quinolin-6-yl, 1-acetyl 2 oxo 3,4-dihydro 2H-quinolin-6-yl, 1-(4thiazolylmethyl)-3,4 dihydro-2H-quinolin-7-yl, 1 acotamidyl-3,4 dihydro-2H-quinolin-7-yl, 1 acetamidyl-2-oxo-3,4-dihydro-2H-quinolin-7-yl, 1-acetamidyl-3,4-dihydro-2H-quinolin-6-yl, 1acetamidyl-2 oxo-3,4-dihydro 2H-quinolin-6-yl, 1-(2 acetylaminoethyl) 3,4-dihydro 2Hquinolin-7-yl, 1 (3 methoxy 3-oxopropyl) 3,4-dihydro-2H-quinolin-7-yl, 1-(3 methoxypropyl)-3,4 dihydro 2H quinolin 7 yl, 1 (2 methoxy-2 oxoethyl) 3,4 dihydro-2H quinolin 7 yl, 1 (2ethoxy-2-excethyl) 3,4-dihydro-2H quinolin-7-yl,-1-(2-acetylaminoethyl) 3,4-dihydro-2Hquinolin-6-yl, 1-(3-mothoxy-3-oxopropyl)-3,4-dihydro-2H quinolin-6-yl, 1-(3-mothoxypropyl)-3,4-dihydro-2H-quinolin-6-yl, 1 (2 mothoxy-2-oxocthyl) 3,4-dihydro-2H quinolin-6-yl, 1 (2ethoxy 2 oxoethyl)-3,4-dihydro 2H quinolin 6-yl, 2-oxo 1,2,3,4-tetrahydro 2H-quinolin 7-yl, 2exo-1,2,3,4 tetrahydro-2II-quinolin 6 yl, 1 (2 acetylaminoethyl) 2 exo-3,4 dihydro 2IIquinolin-7-yl, 1 (3-methoxy 3-oxopropyl) 2-oxo-3,4-dihydro-2H quinolin-7-yl, 1 (3Appl. No 10/811,200
Amdt. December 7, 2004
Reply to Office Action of November 11, 2004
methoxypropyl) 2 oxo 3,4 dihydro 2H quinolin 7 yl, 1 (2 methoxy 2 oxoethyl) 2 oxo 3,4
dihydro 2H quinolin 7 yl, 1 (2 ethoxy 2 oxoethyl) 2 oxo 3,4 dihydro 2H quinolin 7 yl, 1 (2
nectylaminoethyl) 2 oxo 3,4 dihydro 2H quinolin 6 yl, 1 (3 methoxy 3 oxopropyl) 2 oxo 3,4
dihydro 2H quinolin 6 yl, 1 (3 methoxypropyl) 2 oxo 3,4 dihydro 2H quinolin 6 yl, 1 (2
methoxy 2 oxoethyl) 2 oxo 3,4 dihydro 2H quinolin 6 yl, 1 (2 oxo 3,4
dihydro 2H quinolin 6 yl, 1 (2 acetoxyethyl) 2 oxo 3,4 dihydro 2H quinolin 6 yl, 1 (2
nectoxyethyl) 2 oxo 3,4 dihydro 2H quinolin 7 yl, 1 (2 acetoxyethyl) 3,4 dihydro 2H quinolin 6 yl oxo 3,4 dihydro 2H quinolin 7 yl.

49-50. (canceled)

- 51. (currently amended): A compound of claim 44, wherein T is N-substituted 1,2,3,4 tetrahydroquinolin 7-yl, N-substituted 1,2,3,4 tetrahydroquinolin 6-yl, N-substituted 2-oxo-1,2,3,4 tetrahydroquinolin 6-yl, N-substituted 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6-yl, N-substituted 3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-7-yl, N-substituted 2-oxo-4a,8a-dihydro-2H-chromen-7-yl, N-substituted 2,3-dihydroindol-6-yl, N-substituted 2,3-dihydroindol-5-yl, N-substituted 2,3-dihydroindol-5-yl [[,]] or N-substituted 2-oxo-2,3-dihydroindol-5-yl, N-substituted 6-indolyl or N-substituted 5-indolyl.
- 52. (oOriginal): A compound of claim 51, wherein the N-substituent is C_1 - C_6 alkyl, C_1 - C_6 alkyl wherein 1 to 3 nonadjacent carbons are replaced with O, NR ¹⁶, S or a combination thereof, (C_1 - C_6 alkyl)-C(O)- C_1 - C_1 - C_6 alkyl)-C(O)- C_1 - C_1 - C_1 - C_2 - C_1 - C_2 - C_1 - C_2 - C_2
- 53. (original): A compound of claim 44, wherein W is unsubstituted or substituted phenyl.

Reply to Office Action of November 11, 2004

54. (original): A compound of claim 53, wherein W is 2-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 3,5-dimethoxyphenyl, 2-methylphenyl, 3-methylphenyl, 4-fluoro-2-trifluoromethylphenyl, 2-(2-acetoxy-ethyl)-phenyl, 3-(2-acetoxy-ethyl)-phenyl, 4-(2-acetoxy-ethyl)-phenyl, N,N-dimethyl-benzamide-4-yl, or 4-acetylaminophenyl.

- 55. (original): A compound of claim 44, wherein W is 2-methoxyphenyl.
- 56. (currently amended): A compound of claim 44, wherein T is unsubstituted naphthyl [[,]] or unsubstituted 4-trifluoromethylphenyl, unsubstituted 1,2,3,4 tetrahydroquinolin-7 yl, 1-(3-hydroxypropyl) 3,4-dihydro-2H-quinolin-7 yl, or 1 (2 acctoxy-ethyl) 3,4-dihydro-2H-quinolin-7 yl and W is 2-methoxyphenyl.
- 57. (currently amended): The compound
- (4-{4-[3-(2-methoxy-benzyloxy)-propoxy}-phenyl}-piperidin-3-yl)-naphthalen-2-ylmethyl-amine,
- (4-{4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl}-piperidin-3-yl)-(6-methoxy-naphthalen-2-ylmethyl)-amine,
- (4-{4-{3-(2-methoxy-benzyloxy) propoxy}-phonyl}-piperidin-3-yl)-quinolin-7-ylmethyl-amine.
- (4 [4-[3 (2 methoxy benzyloxy) propoxy] phenyl} -piperidin-3-yl) (1,2,3,4 tetrahydro-quinolin-7-ylmethyl)-amino,
- (4-{4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl}-piperidin-3-yl)-methyl-naphthalen-2-ylmethyl-amine,
- 6-[(4-{4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-naphthalen-2-ol,
- benzofuran-5-ylmethyl-(4-[4-[3-(2-methoxy benzyloxy)-propoxy]-phenyl} piperidin-3-yl) amine,

```
Appl. No 10/811,200
Amdt. December 7, 2004
Reply to Office Action of November 11, 2004
(114 indol 5-ylmethyl) (4-{4-{3-(2-methoxy-benzyloxy) propoxy} phenyl} piperidin 3-yl)-
arnine;
```

- 6-[(4-[3-(2-methoxy-benzyloxy)-propoxyl]-phenyl}-piperidin-3-ylamino)-methyl]-naphthalene-1-carboxylic acid methyl ester [[;]].
- 6-[(4-[4-(2-methoxy-benzyloxy)-propoxyl]-phenyl}-piperidin-3-ylamino)-methyl]-naphthalene-1-carboxylic acid[[;]].
- naphthalene-1-carboxylic acid (4-{4-[3-(2-methoxy-benzyloxy)-propoxy]-phenyl}-piperidin-3-yl)-amide[[;]].
- 6-[(4-{4-[3-(2-methoxy-benyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-naphthalene-2-carboxylic acid methyl ester[[;]].
- (4-{4-[3-(2-fluoro-benzyloxy)-propoxy]-phenyl}-piperidin 3-yl)-quinolin 7-ylmethyl-amine;
- 6-[(4-{4-[3-(2-fluoro-benyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-naphthalene-2-carboxylic acid methyl ester[[;]].
- 6-[(4-{4-[3-(2-fluoro-benyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-naphthalene-2-carboxylic acid[[;]],
- 6 [(4-{4-[3-(2-fluoro-benzyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-pyridine-2-carboxylic acid methyl ester;
- naphthalene-2-sulfonic acid (4-{4-[3-(2-fluoro-benzyloxy)-propoxy]-phenyl}-piperidin-3-yl)-amide[[;]],
- (4-{4-[3-(2-fluoro-benzyloxy)-propoxy]-phenyl}-piperidin-3-yl)-(4-fluoro-3-trifluoromethyl-benzyl)-amine[[;]].
- {3-[(4-{4-[3-(2-fluoro-benzyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-phenoxy}-acetic acid methyl ester[[;]],
- 1-(2-{3-[(4-{4-[3-(2-fluoro-benzyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-phenoxy}-ethyl)-pyrrolidine-2,5-dione[[;]] <u>or</u>
- 1-(2-{3-[(4-{4-[3-(2-fluoro-benzyloxy)-propoxy]-phenyl}-piperidin-3-ylamino)-methyl]-phenoxy}-ethyl)-pyrrolidine-2-one[[;]]
- 3-[(1-dimethylcarbamoylmethyl-1, 2, 3, 4 tetrahydro-quinoline 7-carbonyl) amino]-4-[4-[3-(2-methoxy-benzyloxy) propoxy] phenyl}-piperidine 1-earboxylic acid tert-butyl ester; or

Reply to Office Action of November 11, 2004

[1-(2-dimethylamino ethyl)-1, 2, 3, 4-tetrahydro quinolin-7-ylmethyl] (4-{4-[3-(2-methoxybenzyloxy) propoxy]-phenyl}-piperidin-3-yl) amine.

- 58. (currently amended): A pharmaceutical composition comprising a compound of any of claims 1-57 1-19, 27-32, 34-37, 41-48, 51-58, or 67, admixed with a pharmaceutically acceptable carrier, diluent, or excipient.
- 59. (withdrawn): A method of inhibiting renin in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1–57 1–19, 27–32, 34–37, 41–48, 51–58, or 67.
- 60. (withdrawn): A method of treating or preventing hypertension in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1-57 1-19, 27-32, 34-37, 41-48, 51-58, or 67.
- 61. (withdrawn): A method of treating or preventing congestive heart failure in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1-57 1-19, 27-32, 34-37, 41-48, 51-58, or 67.
- 62. (withdrawn): A method of treating or preventing stroke in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1-57 1-19, 27-32, 34-37, 41-48, 51-58, or 67.
- 63. (withdrawn): A method of treating or preventing myocardial infarction in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1-57 1-19, 27-32, 34-37, 41-48, 51-58, or 67.
- 64. (withdrawn): A method of treating or preventing glaucoma in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1-57 1-19, 27-32, 34-37, 41-48, 51-58, or 67.

Reply to Office Action of November 11, 2004

65. (withdrawn): A method of providing end organ protection in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1-57 1-19, 27-32, 34-37, 41-48, 51-58, or 67.

66. (withdrawn): A method of treating or preventing hyperaldosteronism in a mammal comprising administering to the mammal in need thereof an effective amount of a compound of any of claims 1-57 1-19, 27-32, 34-37, 41-48, 51-58, or 67.

67. (original): A process for preparing a compound of claim I comprising the steps of:

a) alkylation of piperidine 1 to afford the intermediate 2 wherein R²⁰, along with the oxygen to which it is attached, is equivalent to -Z-W as defined in claim 1;

b) oxidation of 2 to afford the piperidinone intermediate 3;

Reply to Office Action of November 11, 2004

c) contacting 3 with a suitable amine to afford the intermediate 4, wherein R²¹,

along with the nitrogen to which it is attached is equivalent to -Q-T as defined in claim 1;

d) deprotection of 4 to afford 5